Metformin decreases the incidence of ovarian hyperstimulation syndrome: An experimental study

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Elia, Evelin M ^a   Quintana, Ramiro ^b   Carrere, Carlos ^b   Bazzano, María V ^c   Rey Valzacchi, Gastón ^b   Paz, Dante A ^a,c   Pustovrh, María C ^a,d  

^a INSTITUTO DE FISIOLOGÍA   (Argentina)

^b Procrearte   (Argentina)

^c UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^d UNIVERSIDAD DEL VALLE   (Colombia)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2; ESTRADIOL; EVANS BLUE; METFORMIN; NITRIC OXIDE SYNTHASE; PROGESTERONE; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; BODY WEIGHT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARY FOLLICLE; OVARY HYPERSTIMULATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; WESTERN BLOTTING;

EID: 84883503412     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-62     Document Type: Article

References (54)

1. The role of endothelial cells in the pathogenesis of ovarian hyperstimulation syndrome. Albert C, Garrido N, Mercader A, Rao CV, Remohí J, et al. Mol Hum Reprod 2002 8 5 409 418 10.1093/molehr/8.5.409 11994537 (Pubitemid 34567918)
2. Follicular fluid vascular endothelial growth factor concentrations are elevated in women of advanced reproductive age undergoing ovulation induction. Friedman CI, Danforth DR, Herbosa-Encarnacion C, Arbogast L, Alak BM, et al. Fertil Steril 1997 68 4 607 612 10.1016/S0015-0282(97)00278-1 9341598 (Pubitemid 27454318)
3. Vascular endothelial growth factor levels in serum and plasma from patients undergoing controlled ovarian hyperstimulation for IVF. Manau D, Fábregues F, Peñarrubia J, Creus M, Carmona F, et al. Hum Reprod 2007 22 3 669 675 17079244
4. Inhibition of cyclooxygenase-2 (COX-2) by meloxicam decreases the incidence of ovarian hyperstimulation syndrome in a rat model. Quintana R, Kopcow L, Marconi G, Young E, Yovanovich C, et al. Fertil Steril 2008 90 4, Supplement 1511 1516 10.1016/j.fertnstert.2007.09.028 18166186
5. Physiology and pathology of ovarian hyperstimulation syndrome. Gomez R, Soares SR, Busso C, Garcia-Velasco JA, Simon C, et al. Semin Reprod Med 2010 28 6 448 457 10.1055/s-0030-1265670 21082502
6. Evidences for the existence of a low dopaminergic tone in polycystic ovarian syndrome: implications for OHSS development and treatment. Gomez R, Ferrero H, Delgado-Rosas F, Gaytan M, Morales C, et al. J Clin Endocrinol Metab 2011 96 8 2484 2492 10.1210/jc.2011-0075 21646367
7. Role of nitric oxide, prostaglandins and tyrosine kinase in vascular endothelial growth factor-induced increase in vascular permeability in mouse skin. Fujii E, Irie K, Ohba K, Ogawa A, Yoshioka T, et al. Naunyn Schmiedebergs Arch Pharmacol 1997 356 4 475 480 10.1007/PL00005079 9349634 (Pubitemid 27402087)
8. Oral administration of the cyclooxygenase-2 (COX-2) inhibitor meloxicam blocks ovulation in non-human primates when administered to simulate emergency contraception. Hester KE, Harper MJK, Duffy DM, Hum Reprod 2010 25 2 360 367 10.1093/humrep/dep424 19965877
9. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. Jesam C, Salvatierra AM, Schwartz JL, Croxatto HB, Hum Reprod 2010 25 2 368 373 10.1093/humrep/dep392 19933235
10. Role of AMP-activated protein kinase in mechanism of metformin action. Zhou G, Myers R, Li Y, Chen Y, Shen X, et al. J Clin Invest 2001 108 8 1167 1174 11602624 (Pubitemid 32995375)
11. The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein Kinase through distinct signaling pathways. Fryer LGD, Parbu-Patel A, Carling D, J Biol Chem 2002 277 28 25226 25232 10.1074/jbc.M202489200 11994296 (Pubitemid 34951829)
12. Activation of the AMP-activated Protein Kinase by the Anti-diabetic Drug Metformin in Vivo. Zou M-H, Kirkpatrick SS, Davis BJ, Nelson JS, Wiles WG, et al. J Biol Chem 2004 279 42 43940 43951 10.1074/jbc.M404421200 15265871 (Pubitemid 39390702)
13. Cellular and molecular mechanisms of metformin: an overview. Viollet B, Guigas B, Sanz Garcia N, Leclerc J, Foretz M, et al. Clin Sci (Lond) 2011 122 6 253 270
14. Metformin improves pregnancy and live-birth rates in women with polycystic ovary syndrome (PCOS): a multicenter, double-blind, placebo-controlled randomized trial. Morin-Papunen L, Rantala AS, Unkila-Kallio L, Tiitinen A, Hippelainen M, et al. J Clin Endocrinol Metab 2012 97 5 1492 1500 10.1210/jc.2011-3061 22419702
15. Link between metformin and the peroxisome proliferator-activated receptor γ pathway in the uterine tissue of hyperandrogenized prepubertal mice. Elia EM, Pustovrh C, Amalfi S, Devoto L, Motta AB, Fertil Steril 2011 95 8 2534 2537 e1 10.1016/j.fertnstert.2011.02.004 21382619
16. Pregnancy outcomes and the effect of metformin treatment in women with polycystic ovary syndrome: an overview. Ghazeeri GS, Nassar AH, Younes Z, Awwad JT, Acta Obstet Gynecol Scand 2012 91 6 658 678 10.1111/j.1600-0412.2012.01385.x 22375613
17. The effectiveness of metformin ovulation induction treatment in patients with PCOS: a systematic review and meta-analysis. Xiao J, Chen S, Zhang C, Chang S, Gynecol Endocrinol 2012
18. Effect of metformin pretreatment on pregnancy outcome of in vitro matured oocytes retrieved from women with polycystic ovary syndrome. Wei Z, Cao Y, Cong L, Zhou P, Zhang Z, et al. Fertil Steril 2008 90 4 1149 1154 10.1016/j.fertnstert.2007.07.1385 18022165
19. The mechanisms involved in the action of metformin in regulating ovarian function in hyperandrogenized mice. Elia E, Sander V, Luchetti CG, Solano ME, Di Girolamo G, et al. Mol Hum Reprod 2006 12 8 475 481 10.1093/molehr/gal057 16809378 (Pubitemid 44288192)
20. The effects of metformin on uterine tissue of hyperandrogenized BALB/c mice. Elia EM, Belgorosky D, Faut M, Vighi S, Pustovrh C, et al. Mol Hum Reprod 2009 15 7 421 432 10.1093/molehr/gap033 19482906
21. Metformin prevents embryonic resorption induced by hyperandrogenisation with dehydroepiandrosterone in mice. Solano ME, Elia E, Luchetti CG, Sander V, Di Girolamo G, et al. Reprod Fertil Dev 2006 18 5 533 544 10.1071/RD05099 16836960 (Pubitemid 43806922)
22. Metformin reduces risk of ovarian hyperstimulation syndrome in patients with polycystic ovary syndrome during gonadotropin-stimulated in vitro fertilization cycles: a randomized, controlled trial. Palomba S, Falbo A, Carrillo L, Villani MT, Orio F, et al. Fertil Steril 2011 96 6 1384 1390 e4 10.1016/j.fertnstert.2011.09.020 21982727
23. Role of progesterone in capillary permeability in hyperstimulated rats. Ujioka T, Matsuura K, Kawano T, Okamura H, Hum Reprod 1997 12 8 1629 1634 10.1093/humrep/12.8.1629 9308783 (Pubitemid 27406069)
24. Prevention of ovarian hyperstimulation syndrome in a rat model: efficacy comparison between cabergoline and meloxicam. Saylan A, Arioz DT, Koken T, Dilek H, Saylan F, et al. Acta Obstet Gynecol Scand 2010 89 5 692 699 10.3109/00016341003592537 20423279
25. Involvement of the ANGPTs/Tie-2 system in ovarian hyperstimulation syndrome (OHSS). Scotti L, Abramovich D, Pascuali N, de Zuniga I, Oubina A, et al. Mol Cell Endocrinol 2012 365 2 223 230 23123737
26. Administration of a gonadotropin-releasing hormone agonist affects corpus luteum vascular stability and development and induces luteal apoptosis in a rat model of ovarian hyperstimulation syndrome. Scotti L, Irusta G, Abramovich D, Tesone M, Parborell F, Mol Cell Endocrinol 2011 335 2 116 125 10.1016/j.mce.2011.01.002 21238536
27. Hyperstimulation and a gonadotropin-releasing hormone agonist modulate ovarian vascular permeability by altering expression of the tight junction protein claudin-5. Kitajima Y, Endo T, Nagasawa K, Manase K, Honnma H, et al. Endocrinology 2006 147 2 694 699 Epub 2005 Nov 3. 16269461 (Pubitemid 43112985)
28. Dynamic changes in inhibin messenger RNAs in rat ovarian follicles during the reproductive cycle. Woodruff TK, D'Agostino J, Schwartz NB, Mayo KE, Science 1988 239 4845 1296 1299 10.1126/science.3125611 3125611
29. A role for the androgen receptor in follicular atresia of estrogen receptor beta knockout mouse ovary. Cheng G, Weihua Z, Mäkinen S, Mäkelä S, Saji S, et al. Biol Reprod 2002 66 1 77 84 10.1095/biolreprod66.1.77 11751267 (Pubitemid 34023588)
30. Subfertility and defective folliculogenesis in female mice lacking androgen receptor. Hu Y-C, Wang P-H, Yeh S, Wang R-S, Xie C, et al. Proc Natl Acad Sci USA 2004 101 31 11209 11214 10.1073/pnas.0404372101 15277682 (Pubitemid 39038327)
31. Embryo freezing for preventing ovarian hyperstimulation syndrome. D'Angelo A, Amso N, Cochrane Database Syst Rev 2007 3 D002806 17636707
32. Human albumin does not prevent ovarian hyperstimulation syndrome in assisted reproductive technology program: a prospective randomized placebo-controlled double blind study. Isikoglu M, Berkkanoglu M, Senturk Z, Ozgur K, Fertil Steril 2007 88 4 982 985 Epub 2007 Feb 20 10.1016/j.fertnstert. 2006.11.170 17313946 (Pubitemid 47498350)
33. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study. Engmann L, DiLuigi A, Schmidt D, Nulsen J, Maier D, et al. Fertil Steril 2008 89 1 84 91 Epub 2007 Apr 26 10.1016/j.fertnstert.2007.02.002 17462639
34. The non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial. Busso C, Fernandez-Sanchez M, Garcia-Velasco JA, Landeras J, Ballesteros A, et al. Hum Reprod 2010 25 4 995 1004 doi:10.1093/humrep/deq005. Epub 2010 Feb 6 10.1093/humrep/deq005 20139430
35. Flexible GnRH antagonist protocol versus GnRH agonist long protocol in patients with polycystic ovary syndrome treated for IVF: a prospective randomised controlled trial (RCT). Lainas TG, Sfontouris IA, Zorzovilis IZ, Petsas GK, Lainas GT, et al. Hum Reprod 2010 25 3 683 689 doi:10.1093/humrep/ dep436Epub. 2009 Dec 15 10.1093/humrep/dep436 20008886
36. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Varnagy A, Bodis J, Manfai Z, Wilhelm F, Busznyak C, et al. Fertil Steril 2010 93 7 2281 2284 doi:10.1016/j.fertnstert.2009.01.085. Epub 2009 Mar 3 10.1016/j.fertnstert.2009.01.085 19261278
37. The use of metformin for women with PCOS undergoing IVF treatment. Tang T, Glanville J, Orsi N, Barth JH, Balen AH, Hum Reprod 2006 21 6 1416 25 Epub 2006 Feb 24 10.1093/humrep/del025 16501038 (Pubitemid 44445016)
38. A randomized controlled trial evaluating metformin pre-treatment and co-administration in non-obese insulin-resistant women with polycystic ovary syndrome treated with controlled ovarian stimulation plus timed intercourse or intrauterine insemination. Palomba S, Falbo A, Orio F Jr, Manguso F, Russo T, et al. Hum Reprod 2005 20 10 2879 2886 Epub 2005 Jun 15 10.1093/humrep/dei130 15958399 (Pubitemid 41487647)
39. Adjuncts for ovarian stimulation: when do we adopt "orphan indications" for approved drugs? Meldrum DR, Chang RJ, De-Ziegler D, Schoolcraft WB, Scott RT Jr, et al. Fertil Steril 2009 92 1 13 18 doi:10.1016/j.fertnstert.2009.03.081. Epub 2009 May 6 10.1016/j.fertnstert.2009. 03.081 19423104
40. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. Palomba S, Falbo A, La-Sala GB, BJOG 2013 120 3 267 276 10.1111/1471-0528.12070 23194199
41. Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome. De Leo V, la Marca A, Ditto A, Morgante G, Cianci A, Fertil Steril 1999 72 2 282 285 10.1016/S0015-0282(99)00208-3 10438996 (Pubitemid 29364624)
42. Administration of moderate and high doses of gonadotropins to female rats increases ovarian vascular endothelial growth factor (VEGF) and VEGF receptor-2 expression that is associated to vascular hyperpermeability. Gomez R, Simon C, Remohi J, Pellicer A, Biol Reprod 2003 68 6 2164 2171 12606463 (Pubitemid 36687009)
43. Effect of angiotensin-converting enzyme-inhibiting therapy on the expression of vascular endothelial growth factor in hyperstimulated rat ovary. Ozcakir HT, Giray SG, Ozbilgin MK, Inceboz US, Caglar H, Fertil Steril 2004 82 Suppl 3 1127 1132 15474085 (Pubitemid 39335928)
44. Vascular endothelial growth factor levels in serum and follicular fluid of patients undergoing in vitro fertilization. Lee A, Christenson LK, Stouffer RL, Burry KA, Patton PE, Fertil Steril 1997 68 2 305 311 10.1016/S0015-0282(97) 81520-8 9240261 (Pubitemid 27342606)
45. Alcohol-induced premature permeability in mouse placenta-yolk sac barriers in vivo. Haghighi Poodeh S, Salonurmi T, Nagy I, Koivunen P, Vuoristo J, et al. Placenta 2012 10 866 873
46. VEGFR2 induces c-Src signaling and vascular permeability in vivo via the adaptor protein TSAd. Sun Z, Li X, Massena S, Kutschera S, Padhan N, et al. J Exp Med 2012 209 7 1363 1377 10.1084/jem.20111343 22689825
47. Metformin induces cardioprotection against ischaemia/reperfusion injury in the rat heart 24 hours after administration. Solskov L, Lofgren B, Kristiansen SB, Jessen N, Pold R, et al. Basic Clin Pharmacol Toxicol 2008 103 1 82 87 10.1111/j.1742-7843.2008.00234.x 18484962 (Pubitemid 351874532)
48. Cyclooxygenase-2 activation mediates the proangiogenic effect of nitric oxide in colorectal cancer. Cianchi F, Cortesini C, Fantappie O, Messerini L, Sardi I, et al. Clin Cancer Res 2004 10 8 2694 2704 10.1158/1078-0432.CCR-03- 0192 15102673 (Pubitemid 38509144)
49. COX-2 expression and tumor angiogenesis in colorectal cancer. Wu AW, Gu J, Li ZF, Ji JF, Xu GW, World J Gastroenterol 2004 10 16 2323 2326 15285012 (Pubitemid 39157752)
50. COX-2, VEGF and tumour angiogenesis. Toomey DP, Murphy JF, Conlon KC, Surgeon 2009 7 3 174 180 10.1016/S1479-666X(09)80042-5 19580182
51. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V, Neoplasia 2011 13 5 483 491 21532889
52. The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. Ersoy C, Kiyici S, Budak F, Oral B, Guclu M, et al. Diabetes Res Clin Pract 2008 81 1 56 60 doi:10.1016/j.diabres.2008.02.006 pub 2008 Mar 21 10.1016/j.diabres.2008.02.006 18358555
53. Regulatory effect of hypoxia-inducible factor-1alpha on hCG-stimulated endothelin-2 expression in granulosa cells from the PMSG-treated rat ovary. Zhang J, Zhang Z, Wu Y, Chen L, Luo Q, et al. J Reprod Dev 2012 58 6 678 684 Epub 2012 Aug 20 10.1262/jrd.2012-089 22972036
54. Review: hypoxia-inducible factor-1 (HIF-1): a novel transcription factor in immune reactions. Hellwig-Burgel T, Stiehl DP, Wagner AE, Metzen E, Jelkmann W, J Interferon Cytokine Res 2005 25 6 297 310 10.1089/jir.2005.25.297 15957953 (Pubitemid 40911381)